Index -
P/E -
EPS (ttm) -1.95
Insider Own 10.09%
Shs Outstand 107.08M
Perf Week 7.41%
Market Cap 1.57B
Forward P/E -
EPS next Y -1.85
Insider Trans -0.10%
Shs Float 96.28M
Perf Month -10.18%
Income -207.04M
PEG -
EPS next Q -0.42
Inst Own 84.70%
Short Float 5.76%
Perf Quarter 8.20%
Sales 509.34M
P/S 3.08
EPS this Y 9.68%
Inst Trans 2.97%
Short Ratio 4.46
Perf Half Y -15.13%
Book/sh 3.39
P/B 4.32
EPS next Y -5.30%
ROA -17.71%
Short Interest 5.54M
Perf Year -74.88%
Cash/sh 8.52
P/C 1.72
EPS next 5Y -
ROE -51.52%
52W Range 10.87 - 83.60
Perf YTD -1.94%
Dividend Est. -
P/FCF -
EPS past 5Y -22.97%
ROI -21.60%
52W High -82.49%
Beta 0.41
Dividend TTM -
Quick Ratio 5.56
Sales past 5Y 17.16%
Gross Margin 74.91%
52W Low 34.68%
ATR (14) 0.94
Dividend Ex-Date -
Current Ratio 5.78
EPS Y/Y TTM -120.47%
Oper. Margin -45.63%
RSI (14) 50.23
Volatility 8.04% 5.89%
Employees 1453
Debt/Eq 1.67
Sales Y/Y TTM -5.30%
Profit Margin -40.65%
Recom 2.14
Target Price 26.43
Option/Short Yes / Yes
LT Debt/Eq 1.64
EPS Q/Q -23.90%
Payout -
Rel Volume 9.59
Prev Close 13.07
Sales Surprise -0.01%
EPS Surprise 13.69%
Sales Q/Q 4.17%
Earnings Feb 22 BMO
Avg Volume 1.24M
Price 14.64
SMA20 -2.37%
SMA50 -1.31%
SMA200 -29.81%
Trades
Volume 11,926,038
Change 12.01%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Resumed
JP Morgan
Neutral
$15
Aug-28-23 Downgrade
H.C. Wainwright
Buy → Neutral
$85 → $25
Aug-08-23 Upgrade
Piper Sandler
Neutral → Overweight
$45
Aug-04-23 Initiated
SVB Securities
Outperform
$51
Jul-31-23 Upgrade
Evercore ISI
Underperform → In-line
$33
Jun-07-23 Upgrade
Wedbush
Underperform → Neutral
$53 → $46
May-16-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$70 → $104
Mar-17-23 Downgrade
JP Morgan
Neutral → Underweight
$99 → $50
Jan-06-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$89 → $107
Jan-05-23 Reiterated
H.C. Wainwright
Buy
$100 → $140
Nov-29-22 Upgrade
Wells Fargo
Equal Weight → Overweight
$74 → $89
Oct-24-22 Downgrade
Piper Sandler
Overweight → Neutral
$90 → $70
Jul-05-22 Downgrade
Evercore ISI
In-line → Underperform
May-16-22 Initiated
H.C. Wainwright
Buy
$115
Feb-08-22 Initiated
Loop Capital
Buy
$200
Feb-02-22 Upgrade
Oppenheimer
Perform → Outperform
$98
Jan-20-22 Upgrade
Truist
Hold → Buy
$125
Jan-03-22 Upgrade
Evercore ISI
Underperform → In-line
$82
Jul-01-21 Downgrade
Mizuho
Buy → Neutral
Apr-14-21 Downgrade
Wedbush
Neutral → Underperform
$159 → $154
Show Previous Ratings
Mar-27-24 04:08PM
(Investor's Business Daily) +12.01%
09:29AM
09:16AM
(Investor's Business Daily)
07:14AM
07:12AM
07:05AM
Loading…
07:05AM
07:00AM
Mar-13-24 09:55AM
Mar-11-24 07:00AM
Feb-23-24 11:43AM
Feb-22-24 12:15PM
08:25AM
07:36AM
07:23AM
(Associated Press Finance)
07:00AM
07:46AM
Loading…
Jan-19-24 07:46AM
Jan-18-24 02:19PM
07:00AM
Jan-11-24 09:55AM
Jan-09-24 07:00AM
Jan-08-24 07:00AM
Jan-04-24 04:05PM
Dec-27-23 07:00AM
Dec-08-23 04:09AM
Dec-04-23 04:46PM
Nov-28-23 10:51AM
07:30AM
Nov-21-23 07:00AM
Nov-14-23 09:09AM
Nov-10-23 08:00AM
06:45AM
Loading…
Nov-03-23 06:45AM
Oct-30-23 02:04AM
Oct-28-23 08:39AM
Oct-26-23 04:35PM
11:00AM
08:52AM
08:30AM
07:24AM
(Associated Press Finance)
07:00AM
Oct-15-23 06:05PM
Oct-12-23 08:00AM
Oct-02-23 07:00AM
Sep-29-23 05:00PM
Sep-18-23 11:47AM
Sep-08-23 04:01PM
Sep-06-23 02:27PM
Sep-04-23 09:30AM
Aug-31-23 06:52PM
09:55AM
Aug-29-23 06:31PM
Aug-28-23 05:15PM
04:08PM
(Investor's Business Daily)
02:19PM
(Investor's Business Daily)
12:21PM
12:16PM
12:10PM
11:47AM
09:34AM
07:27AM
07:10AM
07:00AM
Aug-25-23 08:20AM
07:00AM
Aug-15-23 09:30AM
Aug-13-23 05:49PM
Aug-09-23 10:45AM
05:10AM
Aug-08-23 04:11PM
10:02AM
Aug-04-23 09:38AM
Aug-01-23 03:54PM
Jul-27-23 06:56PM
11:30AM
08:15AM
07:07AM
07:00AM
Jul-25-23 10:01AM
Jul-21-23 08:00AM
Jul-06-23 01:17PM
Jul-03-23 08:00AM
Jun-12-23 09:30AM
05:39AM
Jun-09-23 09:45AM
Jun-07-23 11:05AM
Jun-06-23 04:02PM
(Investor's Business Daily) -43.04%
04:01PM
(Investor's Business Daily)
03:40PM
02:48PM
11:50AM
10:31AM
(Investor's Business Daily)
08:31AM
08:12AM
08:05AM
08:00AM
Jun-01-23 07:01AM
May-27-23 06:14AM
May-05-23 09:54AM
05:51AM
May-04-23 01:00PM
08:35AM
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GROENHUYSEN WILHELMUS CM Chief Operating Officer Mar 04 '24 Sale 16.01 1,217 19,484 251,235 Mar 05 04:09 PM Leonard Frank X EVP, Pres., Novocure Oncology Mar 04 '24 Sale 16.01 840 13,448 160,098 Mar 05 04:08 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Mar 01 '24 Sale 16.03 2,107 33,769 252,452 Mar 05 04:09 PM Leonard Frank X EVP, Pres., Novocure Oncology Mar 01 '24 Sale 16.03 1,679 26,909 160,938 Mar 05 04:08 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Feb 28 '24 Sale 16.14 2,303 37,177 254,559 Feb 29 04:28 PM Leonard Frank X EVP, Pres., Novocure Oncology Feb 28 '24 Sale 16.14 2,078 33,545 162,617 Feb 29 04:38 PM Shah Pritesh Chief Growth Officer Nov 07 '23 Sale 12.65 382 4,832 124,511 Nov 08 04:22 PM Cordova Ashley Chief Financial Officer Nov 02 '23 Option Exercise 11.46 175 2,006 117,618 Nov 02 04:20 PM Cordova Ashley Chief Financial Officer Oct 31 '23 Option Exercise 9.58 17,793 170,447 117,443 Nov 02 04:20 PM Cordova Ashley Chief Financial Officer Sep 01 '23 Sale 21.82 883 19,265 99,650 Sep 05 04:24 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Sep 01 '23 Sale 21.82 294 6,414 209,825 Sep 05 04:24 PM Shah Pritesh Chief Growth Officer Sep 01 '23 Sale 21.82 273 5,956 124,893 Sep 05 04:23 PM Cordova Ashley Chief Financial Officer Aug 02 '23 Sale 30.25 1,144 34,607 100,533 Aug 04 04:02 PM
Index -
P/E -
EPS (ttm) -4.65
Insider Own 22.26%
Shs Outstand 6.99M
Perf Week -7.41%
Market Cap 17.48M
Forward P/E -
EPS next Y -4.54
Insider Trans 0.00%
Shs Float 5.44M
Perf Month -10.71%
Income -30.01M
PEG -
EPS next Q -1.20
Inst Own 35.19%
Short Float 0.70%
Perf Quarter -61.72%
Sales 0.00M
P/S -
EPS this Y 22.56%
Inst Trans -8.22%
Short Ratio 0.31
Perf Half Y -65.94%
Book/sh -4.07
P/B -
EPS next Y -27.17%
ROA -53.59%
Short Interest 0.04M
Perf Year 52.44%
Cash/sh 5.87
P/C 0.43
EPS next 5Y -
ROE -
52W Range 1.58 - 13.49
Perf YTD -59.35%
Dividend Est. -
P/FCF -
EPS past 5Y 14.92%
ROI -56.02%
52W High -81.47%
Beta 0.21
Dividend TTM -
Quick Ratio 12.57
Sales past 5Y -20.00%
Gross Margin -
52W Low 58.23%
ATR (14) 0.45
Dividend Ex-Date -
Current Ratio 12.57
EPS Y/Y TTM 22.60%
Oper. Margin 0.00%
RSI (14) 27.67
Volatility 6.29% 7.83%
Employees 9
Debt/Eq -
Sales Y/Y TTM -
Profit Margin -
Recom 3.00
Target Price 11.00
Option/Short No / Yes
LT Debt/Eq -
EPS Q/Q 5.37%
Payout -
Rel Volume 0.28
Prev Close 2.57
Sales Surprise -
EPS Surprise -35.23%
Sales Q/Q -
Earnings Feb 22 BMO
Avg Volume 125.22K
Price 2.50
SMA20 -6.98%
SMA50 -59.29%
SMA200 -64.32%
Trades
Volume 34,722
Change -2.72%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-08-20 Reiterated
H.C. Wainwright
Buy
$20 → $10
May-14-20 Initiated
BTIG Research
Buy
$23
Oct-02-19 Reiterated
Chardan Capital Markets
Buy
$17
Sep-25-19 Initiated
Chardan Capital Markets
Buy
$17
Sep-18-19 Initiated
William Blair
Outperform
May-31-19 Initiated
H.C. Wainwright
Buy
Sep-01-17 Initiated
Citigroup
Buy
$11
Mar-06-17 Resumed
Jefferies
Buy
$17
May-12-16 Resumed
Jefferies
Buy
Feb-27-24 08:11AM
08:00AM
06:31AM
Feb-22-24 07:41AM
(Associated Press Finance) -17.61%
07:00AM
07:47AM
Loading…
Nov-07-23 07:47AM
(Associated Press Finance)
07:30AM
Oct-20-23 01:22PM
Aug-01-23 07:40AM
(Associated Press Finance) +9.15%
07:30AM
Jun-28-23 08:30AM
Jun-09-23 09:55AM
May-18-23 12:00PM
May-15-23 09:57PM
(Thomson Reuters StreetEvents) -11.42%
07:40AM
07:30AM
Loading…
07:30AM
May-10-23 08:00AM
May-08-23 08:30AM
May-01-23 07:00AM
Mar-10-23 02:24AM
Mar-08-23 11:12PM
(Thomson Reuters StreetEvents) -7.65%
07:30AM
Mar-01-23 08:30AM
Dec-29-22 10:18AM
05:30AM
(American City Business Journals)
Dec-28-22 08:00AM
Nov-09-22 08:00AM
Nov-02-22 08:30AM
Oct-20-22 11:28AM
Oct-17-22 09:18AM
08:51AM
Loading…
08:51AM
08:30AM
Sep-26-22 09:21AM
Sep-09-22 04:05PM
Aug-31-22 06:25PM
Aug-23-22 12:38PM
Aug-22-22 08:00AM
Aug-12-22 09:55AM
Aug-09-22 08:00AM
Jun-22-22 08:58AM
May-04-22 08:30AM
Apr-07-22 09:57AM
08:30AM
Mar-21-22 09:52AM
Mar-01-22 09:05AM
07:30AM
Feb-28-22 08:30AM
Dec-01-21 07:44AM
Nov-08-21 08:45AM
07:30AM
Nov-03-21 08:30AM
Nov-01-21 08:30AM
Oct-11-21 08:30AM
Oct-01-21 07:00AM
Sep-30-21 10:32AM
08:30AM
Sep-27-21 08:30AM
Sep-08-21 08:30AM
Aug-02-21 08:55AM
07:30AM
Jul-26-21 03:01PM
08:30AM
Jun-10-21 08:30AM
Jun-04-21 05:20AM
May-28-21 08:00AM
May-19-21 06:19AM
May-17-21 07:57AM
May-13-21 09:01AM
May-12-21 02:35PM
10:03AM
08:30AM
07:30AM
07:20AM
06:59AM
06:45AM
May-11-21 04:15PM
May-05-21 05:10PM
Apr-07-21 08:46AM
Apr-05-21 09:31AM
Mar-08-21 12:30PM
07:30AM
05:30AM
Mar-06-21 10:57AM
Mar-01-21 08:30AM
Feb-08-21 02:30PM
01:20PM
12:30PM
11:30AM
11:13AM
11:00AM
09:43AM
06:20AM
12:45AM
Feb-07-21 01:12PM
10:30AM
Feb-06-21 01:10PM
10:00AM
07:15AM
Feb-05-21 09:15PM
09:00PM
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson's disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Luthringer Remy CEO May 02 '23 Sale 3.76 3,641 13,690 68,994 May 02 06:15 PM Luthringer Remy CEO May 01 '23 Sale 3.85 23,753 91,449 72,635 May 02 06:15 PM Race Geoff President May 01 '23 Sale 3.85 22,082 85,016 51,324 May 02 06:14 PM Ahlholm Frederick W SVP, CFO and Secretary May 01 '23 Sale 4.48 3,580 16,038 17,518 May 02 06:13 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite